Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -7.46% and Operating profit at -223.58% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Sep 25
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,595 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.44
-19.50%
5.78
Revenue and Profits:
Net Sales:
149 Million
(Quarterly Results - Mar 2026)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.54%
0%
-40.54%
6 Months
-32.02%
0%
-32.02%
1 Year
49.52%
0%
49.52%
2 Years
-25.0%
0%
-25.0%
3 Years
-36.04%
0%
-36.04%
4 Years
-38.49%
0%
-38.49%
5 Years
-49.07%
0%
-49.07%
Shanghai Fudan Forward S&T Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-7.46%
EBIT Growth (5y)
-223.58%
EBIT to Interest (avg)
-0.21
Debt to EBITDA (avg)
6.86
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
0.57
Tax Ratio
1.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.03%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.11
EV to EBIT
86.32
EV to EBITDA
48.70
EV to Capital Employed
4.71
EV to Sales
6.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
5.45%
ROE (Latest)
-19.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
149.10
147.40
1.15%
Operating Profit (PBDIT) excl Other Income
-8.70
-152.90
94.31%
Interest
3.70
4.40
-15.91%
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
-11.20
-181.30
93.82%
Operating Profit Margin (Excl OI)
-58.10%
-1,128.60%
107.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 1.15% vs -11.42% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 93.82% vs -1,462.93% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
638.00
642.90
-0.76%
Operating Profit (PBDIT) excl Other Income
-126.00
-64.60
-95.05%
Interest
14.20
15.70
-9.55%
Exceptional Items
-14.20
-10.20
-39.22%
Consolidate Net Profit
-201.20
-135.00
-49.04%
Operating Profit Margin (Excl OI)
-278.00%
-182.40%
-9.56%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -0.76% vs -5.06% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -49.04% vs -542.86% in Dec 2024
About Shanghai Fudan Forward S&T Co., Ltd. 
Shanghai Fudan Forward S&T Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






